NDC 57664-048 – Lisdexamfetamine Dimesylate
Lisdexamfetamine Dimesylate 30 mg/1 · Capsule · Oral
Product NDC57664-048
Product details
- Brand name
- Lisdexamfetamine Dimesylate
- Generic name
- Lisdexamfetamine Dimesylate
- Labeler
- Sun Pharmaceutical Industries, Inc.
- Dosage form
- Capsule
- Route
- Oral
- Marketing category
- ANDA · ANDA214484
- Marketed since
- August 25, 2023
- Listing expires
- December 31, 2027
- Pharmacologic class
- Central Nervous System Stimulant
Active ingredients
- Lisdexamfetamine Dimesylate 30 mg/1
Uses, dosage, side effects and warnings for lisdexamfetamine dimesylate →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 57664-048-88 | 100 CAPSULE in 1 BOTTLE (57664-048-88) | Aug 25, 2023 |
Recalls mentioning this NDC
- D-0148-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0150-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0145-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0146-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0144-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0149-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0147-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0516-2025 Jul 23, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH).
Other lisdexamfetamine dimesylate products
- 47781-568 Lisdexamfetamine Dimesylate 70 mg/1 · Capsule · Alvogen Inc.
- 47781-565 Lisdexamfetamine Dimesylate 40 mg/1 · Capsule · Alvogen Inc.
- 47781-564 Lisdexamfetamine Dimesylate 30 mg/1 · Capsule · Alvogen Inc.
- 47781-562 Lisdexamfetamine Dimesylate 10 mg/1 · Capsule · Alvogen Inc.
- 47781-563 Lisdexamfetamine Dimesylate 20 mg/1 · Capsule · Alvogen Inc.
- 47781-567 Lisdexamfetamine Dimesylate 60 mg/1 · Capsule · Alvogen Inc.
- 47781-566 Lisdexamfetamine Dimesylate 50 mg/1 · Capsule · Alvogen Inc.
- 60687-929 Lisdexamfetamine Dimesylate 50 mg/1 · Capsule · American Health Packaging
- 60687-940 Lisdexamfetamine Dimesylate 60 mg/1 · Capsule · American Health Packaging
- 60687-918 Lisdexamfetamine Dimesylate 40 mg/1 · Capsule · American Health Packaging
- 60687-896 Lisdexamfetamine Dimesylate 20 mg/1 · Capsule · American Health Packaging
- 60687-907 Lisdexamfetamine Dimesylate 30 mg/1 · Capsule · American Health Packaging